Cas:81633-77-4 (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide manufacturer & supplier

We serve Chemical Name:(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide CAS:81633-77-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide

Chemical Name:(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide
CAS.NO:81633-77-4
Synonyms:(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide
Molecular Formula:C16H18BrNO2
Molecular Weight:336.22400
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:491.7ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:52.49000
Exact Mass:335.05200
LogP:3.66230

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide Use and application,(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide technical grade,usp/ep/jp grade.


Related News: In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide manufacturer If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role. (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide supplier Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide vendor In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine. (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diolhydrobromide factory Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report.